A Phase 2 interventional study of Zibotentan and Dapagliflozin in Chronic Kidney Disease, sponsored by AstraZeneca. Completed at 164 sites in 19 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-07-30.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Renal Insufficiency, Chronic by AstraZeneca — 6 open to participants now, 11 under way, 5 of them phase 3. Renal Insufficiency, Chronic · AstraZeneca.
Among the 54 studies in Renal Insufficiency, Chronic by AstraZeneca, this one is the 13th largest by enrollment of the 38 interventional ones that give a count, is one of 8 that started in 2021, is one of 9 in phase 2, and was the 18th registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →6 of the 54 studies in Renal Insufficiency, Chronic by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Austria and 24 more countries
Ages 18–99
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 18+
AstraZeneca · Sites in China
AstraZeneca · Sites in United States
Ages 18–75 · Healthy volunteers
AstraZeneca · Sites in United States, Argentina, Australia and 39 more countries
Ages 18+
By country, each count listing its studies:
Of the 435 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 111 (26%) stop at 75 or younger; 45 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 8 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 542 is above the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 170 across the 38 interventional studies, 4,000 across the 16 observational. Of the 43 that completed or were terminated, 18 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
3 of the studies in Renal Insufficiency, Chronic by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07222917AstraZenecaA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. | 2026-12-10 |
| NCT07024823AstraZenecaA Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in Healthy Participants, Participants With CKD and Type 2 Diabetes, Assess Home Measurements of Creatinine in a Non-Interventional Cohort, and Assess the Effect of AZD4248 on the PK of Midazolam and Metformin in Healthy Participants | 2027-01-29 |
| NCT06610526AstraZenecaA Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease | 2027-05-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies in Renal Insufficiency, Chronic by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess efficacy, safety and tolerability of treatment with zibotentan and dapagliflozin in combination and dapagliflozin 10 mg as monotherapy in participants with chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) ≥ 20 mL/min/1.73 m\^2, and urinary albumin to creatinine ratio (UACR) ≥ 150 mg/g and ≤ 5000 mg/g.
The study will be conducted in approximately 220 sites in North America, South America, Africa, Asia/Pacific, and European countries.
Participants will be randomized to 12 weeks of treatment plus 2 weeks follow-up.
After screening, eligible participants will be stratified by diabetes (diabetic kidney disease [DKD] versus non-diabetes mellitus [non-DM] CKD) and baseline eGFR (below or equal versus above 45 mL/min/1.73m\^2).
A total of 495 participants will be randomised into this study, including participants randomised under the earlier study design. Four hundred and fifteen (415) participants will be randomised to have 166 participants in zibotentan Dose A/dapagliflozin 10 mg combination arm and dapagliflozin 10 mg monotherapy arm, and 83 participants in the zibotentan Dose B/dapagliflozin 10 mg combination arm.
Participants who were previously randomised cannot be re-randomised.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants are eligible to be included in the study only if all of the following criteria apply:
Diagnosis of Chronic kidney disease (CKD), defined as:
(a) chronic kidney disease epidemiology collaboration (CKD-EPI) ≥ 20 mL/min/1.73 m\^2, and (b) UACR ≥ 150 and ≤ 5000 mg albumin/g creatinine, based on a single first morning void spot urine sample at screening.
Female participants must have a negative pregnancy test at screening, must not be lactating, and must be of non-childbearing potential, confirmed at screening by fulfilling one of the following criteria:
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
Any clinically significant disease or disorder (eg, cardiovascular, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, psychiatric, major physical impairment), which might put the participant at risk because of participation in the study, or probable alternative primary reason for participant's symptoms in judgment of investigator, including but not limited to:
Confirmation of corona virus disease- 2019 (COVID-19) infection:
Participants can decline to participate in the genetic research and may still participate in the study. Exclusion from this optional genetic research may be for any of the exclusion criteria specified for the main study or any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive once daily oral dose A of zibotentan and 10 mg dapagliflozin for 12 weeks.
Drug: Zibotentan · Drug: Dapagliflozin
Participants will receive once daily oral dose B of zibotentan and 10 mg dapagliflozin for 12 weeks.
Drug: Zibotentan · Drug: Dapagliflozin
Participants will receive once daily oral dose of dapagliflozin 10 mg and placebo for 12 weeks.
Drug: Dapagliflozin · Drug: Placebo
Participants will receive zibotentan as per the arms they are randomized.
Participants will receive 10 mg dapagliflozin as per the arms they are randomized.
Participants will receive placebo as per the arms they are randomized to.
Change in Urinary Albumin to Creatinine Ratio (UACR) From Baseline to Week 12
The effect of zibotentan 1.5/dapagliflozin 10 mg versus dapagliflozin 10 mg on UACR was assessed.
Time frame: From baseline (Week 0 [Day 1]) until Week 12 (Day 84)
Change in UACR From Baseline to Week 12
The effect of zibotentan 0.25 mg/dapagliflozin 10 mg versus dapagliflozin 10 mg monotherapy on UACR was assessed.
Time frame: From baseline (Week 0 [Day 1]) until Week 12
Change in Office Systolic Blood Pressure From Baseline to Week 12
The change in office systolic blood pressure for doses of zibotentan combined with dapagliflozin 10 mg versus dapagliflozin 10 mg monotherapy was assessed.
Time frame: From baseline (Week 0 [Day 1]) until Week 12 (Day 84)
Change in Office Diastolic Blood Pressure From Baseline to Week 12
The change in office diastolic blood pressure for doses of zibotentan combined with dapagliflozin 10 mg versus dapagliflozin 10 mg monotherapy was assessed.
Time frame: From baseline (Week 0 [Day 1]) until Week 12 (Day 84)
Change in UACR From Baseline to Week 12
The assessment of dose-response and relationship across different dose of zibotentan/dapagliflozin and dapagliflozin alone on UACR reduction.
Time frame: From baseline (Week 0 [Day 1]) until Week 12 (Day 84)
Change in eGFR From Baseline to Week 1, Week 12, and Week 14
The effect of different doses of zibotentan and dapagliflozin 10 mg in combination versus dapagliflozin 10 mg monotherapy on eGFR was assessed.
Time frame: From baseline (Week 0 [Day 1]) until Week 1 (Day 8), Week 12 (Day 84), and Week 14 (Day 98)
Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
The safety and tolerability of all doses of zibotentan combined with dapagliflozin 10 mg and dapagliflozin 10 mg monotherapy was assessed.
Time frame: From Screening (Day -28) until Follow-up visit (Day 98), up to 126 days
Change in eGFR From Week 1 to Week 12
The effect of different doses of zibotentan and dapagliflozin 10 mg in combination versus dapagliflozin 10 mg monotherapy on eGFR was assessed.
Time frame: From Week 1 (Day 8) to Week 12 (Day 84)
The study was conducted in approximately 170 sites in North America, South America, Africa, Asia/Pacific, and European countries.
| Milestone | Zibotentan 0.25 mg + Dapagliflozin | Zibotentan 1.5 mg + Dapagliflozin | Placebo + Dapagliflozin |
|---|---|---|---|
| Started | 91 | 179 | 177 |
| Full analysis set | 91 | 179 | 177 |
| Safety analysis set | 91 | 179 | 177 |
| Completed | 82 | 142 | 157 |
| Not completed | 9 | 37 | 20 |
| Withdrew: Other | 4 | 16 | 0 |
| Withdrew: Withdrawal by subject | 2 | 9 | 9 |
| Withdrew: Adverse event | 2 | 7 | 4 |
| Withdrew: Lost to follow-up | 0 | 1 | 3 |
| Withdrew: Physician decision | 1 | 2 | 0 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Failure to meet randomization criteria | 0 | 1 | 3 |
| Withdrew: Study terminated by sponsor | 0 | 1 | 0 |
The effect of zibotentan 1.5/dapagliflozin 10 mg versus dapagliflozin 10 mg on UACR was assessed.
| milligram/gram (mg/g) | Zibotentan 1.5 mg + Dapagliflozin | Placebo + Dapagliflozin |
|---|---|---|
| Change in Urinary Albumin to Creatinine Ratio (UACR) From Baseline to Week 12 | 0.48 ± 1.094 | 0.72 ± 1.090 |
The effect of zibotentan 0.25 mg/dapagliflozin 10 mg versus dapagliflozin 10 mg monotherapy on UACR was assessed.
| mg/g | Zibotentan 0.25 mg + Dapagliflozin | Placebo + Dapagliflozin |
|---|---|---|
| Change in UACR From Baseline to Week 12 | 0.52 ± 1.106 | 0.72 ± 1.090 |
The change in office systolic blood pressure for doses of zibotentan combined with dapagliflozin 10 mg versus dapagliflozin 10 mg monotherapy was assessed.
| Millimeters of mercury (mmHg) | Zibotentan 0.25 mg + Dapagliflozin | Zibotentan 1.5 mg + Dapagliflozin | Placebo + Dapagliflozin |
|---|---|---|---|
| Change in Office Systolic Blood Pressure From Baseline to Week 12 | -7.1 (-10.0 to -4.1) | -11.0 (-13.5 to -8.4) | -3.4 (-5.8 to -1.0) |
The change in office diastolic blood pressure for doses of zibotentan combined with dapagliflozin 10 mg versus dapagliflozin 10 mg monotherapy was assessed.
| mmHg | Zibotentan 0.25 mg + Dapagliflozin | Zibotentan 1.5 mg + Dapagliflozin | Placebo + Dapagliflozin |
|---|---|---|---|
| Change in Office Diastolic Blood Pressure From Baseline to Week 12 | -4.3 (-6.2 to -2.5) | -6.8 (-8.4 to -5.2) | -1.4 (-2.9 to 0.1) |
The assessment of dose-response and relationship across different dose of zibotentan/dapagliflozin and dapagliflozin alone on UACR reduction.
| mg/g | Zibotentan 0.25 mg + Dapagliflozin | Zibotentan 1.5 mg + Dapagliflozin | Placebo + Dapagliflozin |
|---|---|---|---|
| Change in UACR From Baseline to Week 12 | 0.52 ± 1.106 | 0.48 ± 1.094 | 0.72 ± 1.090 |
The effect of different doses of zibotentan and dapagliflozin 10 mg in combination versus dapagliflozin 10 mg monotherapy on eGFR was assessed.
| milliliters/minutes/1.73 square metres | Zibotentan 0.25 mg + Dapagliflozin | Zibotentan 1.5 mg + Dapagliflozin | Placebo + Dapagliflozin |
|---|---|---|---|
| Week 1 | -2.0 (-3.5 to -0.5) | -3.9 (-5.2 to -2.6) | -3.1 (-4.4 to -1.8) |
| Week 12 | -3.1 (-4.7 to -1.5) | -3.0 (-4.4 to -1.6) | -1.9 (-3.3 to -0.6) |
| Week 14 | 0.2 (-1.4 to 1.8) | -2.0 (-3.4 to -0.6) | 0.1 (-1.2 to 1.5) |
The safety and tolerability of all doses of zibotentan combined with dapagliflozin 10 mg and dapagliflozin 10 mg monotherapy was assessed.
| Participants | Zibotentan 0.25 mg + Dapagliflozin | Zibotentan 1.5 mg + Dapagliflozin | Placebo + Dapagliflozin |
|---|---|---|---|
| Any AE | 45 | 86 | 66 |
| AE with outcome of death | 0 | 0 | 1 |
| Any SAE | 2 | 10 | 4 |
| Any AE leading to discontinuation of investigational product (IP) | 11 | 22 | 7 |
| Any AE leading to dose interruption | 3 | 7 | 10 |
| Any AE leading to withdrawal from study | 2 | 7 | 4 |
| Any AE possibly related to IP | 14 | 33 | 16 |
The effect of different doses of zibotentan and dapagliflozin 10 mg in combination versus dapagliflozin 10 mg monotherapy on eGFR was assessed.
| milliliters/minutes/1.73 square metres | Zibotentan 0.25 mg + Dapagliflozin | Zibotentan 1.5 mg + Dapagliflozin | Placebo + Dapagliflozin |
|---|---|---|---|
| Change in eGFR From Week 1 to Week 12 | -1.1 (-2.5 to 0.4) | 0.9 (-0.2 to 2.0) | 1.2 (0.1 to 2.2) |
Collected over From screening (Day -28) to Final Follow-up (Day 98), up to 126 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zibotentan 0.25 mg + Dapagliflozin | 0/91 (0%) | 2/91 (2.2%) | 14/91 (15.4%) |
| Zibotentan 1.5 mg + Dapagliflozin | 0/179 (0%) | 10/179 (5.6%) | 24/179 (13.4%) |
| Placebo + Dapagliflozin | 1/177 (0.6%) | 4/177 (2.3%) | 6/177 (3.4%) |
| Event | Zibotentan 0.25 mg + Dapagliflozin | Zibotentan 1.5 mg + Dapagliflozin | Placebo + Dapagliflozin |
|---|---|---|---|
| Cardiac failure congestiveCardiac disorders | 1/91 | 0/179 | 0/177 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/91 | 0/179 | 0/177 |
| GastroenteritisInfections and infestations | 0/91 | 0/179 | 1/177 |
| RestlessnessPsychiatric disorders | 0/91 | 0/179 | 1/177 |
| Acute kidney injuryRenal and urinary disorders | 0/91 | 1/179 | 1/177 |
| Sudden cardiac deathGeneral disorders | 0/91 | 0/179 | 1/177 |
| Cerebrovascular accidentNervous system disorders | 0/91 | 1/179 | 0/177 |
| Acute myocardial infarctionCardiac disorders | 0/91 | 1/179 | 0/177 |
| Cardiac failureCardiac disorders | 0/91 | 1/179 | 0/177 |
| Chronic left ventricular failureCardiac disorders | 0/91 | 1/179 | 0/177 |
| Event | Zibotentan 0.25 mg + Dapagliflozin | Zibotentan 1.5 mg + Dapagliflozin | Placebo + Dapagliflozin |
|---|---|---|---|
| HeadacheNervous system disorders | 6/91 | 8/179 | 2/177 |
| Metabolic acidosisMetabolism and nutrition disorders | 5/91 | 7/179 | 2/177 |
| HypertensionVascular disorders | 5/91 | 0/179 | 1/177 |
| Brain natriuretic peptide increasedInvestigations | 2/91 | 9/179 | 1/177 |
The full analysis set included all participants who were randomised and received any study intervention.
| Age, Continuous(Years) | Zibotentan 0.25 mg + Dapagliflozin | Zibotentan 1.5 mg + Dapagliflozin | Placebo + Dapagliflozin | Total |
|---|---|---|---|---|
| Mean | 61.3 ± 12.72 | 62.7 ± 12.33 | 63.6 ± 11.60 | 62.8 ± 12.13 |
| Sex: Female, Male(Participants) | Zibotentan 0.25 mg + Dapagliflozin | Zibotentan 1.5 mg + Dapagliflozin | Placebo + Dapagliflozin | Total |
|---|---|---|---|---|
| Female | 28 | 55 | 55 | 138 |
| Male | 63 | 124 | 122 | 309 |
| Ethnicity (NIH/OMB)(Participants) | Zibotentan 0.25 mg + Dapagliflozin | Zibotentan 1.5 mg + Dapagliflozin | Placebo + Dapagliflozin | Total |
|---|---|---|---|---|
| Hispanic or Latino | 23 | 58 | 46 | 127 |
| Not Hispanic or Latino | 68 | 121 | 131 | 320 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Zibotentan 0.25 mg + Dapagliflozin | Zibotentan 1.5 mg + Dapagliflozin | Placebo + Dapagliflozin | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 18 | 26 | 26 | 70 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 0 | 2 |
| Black or African American | 7 | 17 | 22 | 46 |
| White | 56 | 124 | 125 | 305 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 10 | 10 | 4 | 24 |
Showing the first 100 of 164 sites across 19 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Apr 2021 to primary completion in Jun 2023, 25 months.
Results were first posted in Jul 2024, 1 year 1 month after primary completion.
Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 25 months is above that.
Counting every sponsor, half of 139 studies reached it within 25 months; a quarter within 15 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ZD4054
Renal Insufficiency, Chronic →